Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group

Journal of Clinical Oncology

Volumn 18, Issue 6, 2000, Pages 1193-1202

  Piccart, Martine J ^a   Green, John A ^a   Lacave, Angel Jimenez ^a   Reed, Nick ^a   Vergote, Ignace ^a   Benedetti Panici, Pierluigi ^a   Bonetti, Andrea ^a   Kristeller Tome, Vera ^a   Fernandez, Cesar Mendiola ^a   Curran, Desmond ^a   Van Glabbeke, Martine ^a   Lacombe, Denis ^a   Pinel, Marie Claire ^a   Pecorelli, Serge ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

OXALIPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROTOXICITY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034064719     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1193     Document Type: Article

References (60)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1559, 1993
2. McGuire W, Hoskins W, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
3. Ozols RF: Treatment of ovarian cancer: Current status. Semin Oncol 21:1-9, 1994
4. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al: Long-term survival in ovarian cancer. Eur J Cancer 27:1367-1372, 1991
5. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
6. Bertelsen K, Kaern J, Simonsen E, et al: Is cisplatin-taxol (PT) the standard treatment in advanced ovarian cancer? Eur J Cancer 33:614, 1998 (abstr)
7. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
8. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Onclogy Group study. J Clin Oncol 12:1748-1753, 1994
9. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
10. Omura G, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150, 1991
11. Burchenal J, Irani G, Kern K, et al: 1,2-diaminocyclohexane platinum derivatives of potential clinical values, in Mathé G, Muggia F (eds): Recent Results in Cancer Research: Cancer Chemo-and Immuno-pharmacology. Berlin, Springer-Verlag, 1980, pp 146-155
12. Pendyala L, Creaven PJ: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53:5970-5976, 1993
13. Fink D, Nebel S, Norris PS, et al: Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 77:741-746, 1998
14. Alvarez M, Ortuzar W, Rixe O, et al: Cross-resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogues. Proc Annu Meet Am Assoc Cancer Res 35:439, 1994 (abstr)
15. Rixe O, Ortuzar W, Alvarez M, et al: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865, 1996
16. Ortuzar W, Paull K, Rixe O, et al: Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistant sublines. Proc Annu Meet Am Assoc Cancer Res 35:332, 1994 (abstr)
17. Mathé G, Chenu E, Bourut C, et al: Experimental study of three platinum complexes: CDDP, CBDCA and L-OHP on L1210 leukemia - Alternate or simultaneous association of two platinum complexes. Proc Annu Meet Am Assoc Cancer Res 30:471, 1989 (abstr)
18. Extra JM, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25: 299-303, 1990
19. Brienza S, Vignoud J, Itzhaki M, et al: Oxaliplatin (L-OHP): Global safety in 682 patients (pts). Eur J Cancer 31A:S194, 1995 (suppl, abstr 933)
20. Brienza S, Fandi A, Hugret F, et al: Neurotoxicity (NTX) of long-term oxaliplatin (L-OHP) therapy. Proc Annu Meet Am Assoc Cancer Res 34:406, 1993 (abstr)
21. Aebi S, Kurdihaidar B, Gordon R, et al: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 53:3087-3090, 1996
22. Fink D, Zheng H, Nebel S, et al: In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57:1841-1845, 1997
23. Misset JL, Kidani Y, Gastiaburu J et al, et al: Oxalatoplatinum (L-OHP): Experimental and clinical studies, in Howell S (ed): Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. New York, New York, Plenum Press, 1991, pp 369-375
24. Chollet P, Bensmaine A, Brienza S, et al: Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7:1065-1070, 1996
25. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 31:103-115, 1975
26. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
27. Eisenhauer EA, Vermorken JB, van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 8:963-968, 1997
28. Creemers GJ, Bolis G, Gore M, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14:3056-3061, 1996
29. Armstrong D, Rowinsky EK, Donehower R, et al: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:275a, 1995 (abstr 769)
30. Kudelka A, Tresukosol D, Edwards CL, et al: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996
31. Gordon A, Bookman MA, Malmstrom H, et al: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial. Proc Am Soc Clin Oncol 15:282a, 1996 (abstr 763)
32. Bookman MA, Malmstrom H, Bolis G, et al: Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label, phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345-3352, 1998
33. Francis P, Schneider J, Hann L, et al: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12:2301-2308, 1994
34. Piccart M, Gore M, ten Bokkel Huinink WW, et al: Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87:676-681, 1995
35. Kaye SB, Piccart M, Aapro M, et al: Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trials-EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Eur J Cancer 31A:S14-S17, 1995 (suppl 4)
36. Moore D, Valea F, Grumpler LS, et al: Hexamethylmelamine/ altretamine as second-line therapy for epithelial ovarian carcinoma. Gynecol Oncol 51:109-112, 1993
37. Manetta A, Krishnansu T, Edwards S, et al: Hexamethylmelamine as a single second line agent in ovarian cancer: Follow-up report and review of the literature. Gynecol Oncol 66:20-26, 1997
38. Vergote I, Himmelmann A, Bo Frankendal PH, et al: Hexamethylmelamine as second line therapy in platin-resistant ovarian cancer. Gynecol Oncol 47:282-286, 1992
39. Markman M, Blessing JA, Moore D, et al: Altretamine (Hexamethylmelamine) in platinum resistant and platinum refractory ovarian cancer: A Gynecologic Oncology Group phase II trial. Gynecol Oncol 69:226-229, 1998
40. Rose G, Blessing A, Mayer R, et al: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 16:405-410, 1998
41. Hoskins J, Swenerton KD: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60-63, 1994
42. Marzola M, Zuchetti M, Colombo N, et al: Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 4:517-519, 1993
43. Markman M, Hakes T, Reichman B, et al: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 10:243-248, 1992
44. Sutton GP, Blessing JA, Homesley HD, et al: Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 7:1672-1676, 1989
45. Wils J, Geuns HV, Wals J, et al: Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony stimulating factor) in relapsed ovarian cancer: A study of the Gynecologic Study Group of the Comprehensive Cancer Center Limburg. Anticancer Drugs 8:432-435, 1997
46. Evans BD, Rajo KS, Calvert AH, et al: Phase II study of JM 8, a new platinum analog in advanced ovarian carcinoma. Cancer Treat Rep 67:997-1000, 1983
47. Eisenhauer EA, Swenerton KD, Sturgeon J, et al: Phase II study of carboplatin in patients with ovarian carcinoma: A National Cancer Institute of Canada Trials Groups Study. Cancer Treat Rep 70:1195-1198, 1986
48. Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530-1533, 1994
49. Muggia F, Braly P, Brady MF, et al: Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132. Proc Am Soc Clin Oncol 16:352a, 1997 (abstr 1257)
50. Bajetta E, Di Leo A, Biganzoli L, et al: Phase D study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 14:2546-2551, 1996
51. Sugiyama T, Takeuchi S, Yakushiji M: Phase I study of irinotecan (cpt-11) in combination with cisplatin (cddp) on cervical carcinoma. Proc Am Soc Clin Oncol 13:856a, 1994 (abstr)
52. Kaufmann M, Bauknecht T, Jonat W, et al: Gemcitabine (GEM) in cisplatin-resistant ovarian cancer. Proc Am Soc Clin Oncol 14:272a, 1994 (abstr)
53. Underbill C, Parnis FX, Highley M, et al: A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 15:290a, 1996 (abstr)
54. Vermorken JB, Bolis G, Van Rijswijk REN, et al: High-dose intensity regimens with epirubicin in ovarian cancer. Semin Oncol 21:17-22, 1994
55. Dieras V, Bougnoux P, Petit T, et al: Oxaliplatin (L-OHP) phase II study in platinum (PT) pretreated advanced ovarian cancer (AOC): Preliminary results. Proc Am Soc Clin Oncol 17:364a, 1998 (abstr 1405)
56. Faivre S, Kalla S, Cvitkovic E, et al: Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate use experience. Ann Oncol 10:1125-1128, 1999
57. Kalla S, Faivre S, Bensmaine A, et al: Paclitaxel (PXL)-oxaliplatin (L-OHP): A feasible active combination in heavily pretreated advanced ovarian carcinoma (ADOVCA) patients (PTS). Proc Am Soc Clin Oncol 17:357a, 1998 (abstr 1378)
58. Misset J, Chollet P, Vennin P, et al: Multicentric phase H-III trial of oxaliplatin (LOHP) versus cisplatin (P) both in association with cyclophosphamide (C) in the treatment of advanced ovarian cancer (AOC): Toxicity efficacy results. Proc Am Soc Clin Oncol 16:354a, 1997 (abstr 1266)
59. Soulié P, Bensmaine A, Garrino C, et al: Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 33:1400-1406, 1997
60. Delaloge S, Laadem A, Chouaki N, et al: Feasability study of the paclitaxel (PXL), oxaliplatin (LOHP) and cisplatin (CDDP) combination in advanced ovarian cancer (AOC) patients (PTS). Proc Am Soc Clin Oncol 18:365a, 1999 (abstr 1409)